Original articleAlimentary tractAssociation Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Section snippets
Patients
We conducted a cross-sectional study including all patients with CD or UC receiving ADA maintenance therapy and undergoing routine endoscopy (evaluation of disease activity or screening for dysplasia). Evaluation of endoscopic disease activity (X.R. and E.D.T), and therapeutic drug monitoring of ADA between June 2011 and June 2012 were analyzed. This was a prospective observational study enrolling patients treated at Saint-Etienne University Hospital. The total Mayo score for UC and the Crohn's
Results
A total of 40 IBD patients could be analyzed. Patient characteristics are reported in Table 1. The mean age of the patients was 42.7 years with a sex ratio (male:female) of 0.8. The mean ADA duration was 10.7 months and the median CRP level was 14 mg/mL (16 mg/mL (range, 7–18) for CD and 12 mg/mL (range, 3–20) for UC). A total of 22 patients had CD: 31% of them were in clinical remission (N = 7) and 36% had MH (N = 8). Eighteen patients had UC and 33% were in clinical remission (N = 6), and 44%
Discussion
This study investigated the association between mucosal healing and therapeutic drug monitoring of ADA in patients with IBD. There is growing evidence that therapeutic drug monitoring of anti-TNF agents (infliximab, ADA) is associated with clinical outcomes.
In a recent meta-analysis, the presence of antibodies to infliximab was associated with a significantly higher risk of loss of clinical response to infliximab and lower serum infliximab levels in patients with IBD.13
In a
References (16)
- et al.
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
Gastroenterology
(2007) - et al.
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease
Gastroenterology
(2009) - et al.
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Clin Gastroenterol Hepatol
(2006) - et al.
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial
Gastroenterology
(2012) - et al.
Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients
J Crohn's Colitis
(2013) - et al.
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
Gastroenterology
(2012) - et al.
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up
JAMA
(2011) - et al.
Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis
J Dermatol
(2013)
Cited by (255)
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
2023, The Lancet Gastroenterology and HepatologyReply
2023, GastroenterologyPrecision medicine and drug optimization in adult inflammatory bowel disease patients
2023, Therapeutic Advances in Gastroenterology
Conflicts of interest These authors disclose the following: Laurent Peyrin–Biroulet has received lecture and consulting fees from Abbvie and MSD, and Xavier Roblin has received lecture and consulting fees from Merck. The remaining authors disclose no conflicts.